Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma.
Rook AH, Gelfand JM, Wysocka M, Troxel AB, Benoit B, Surber C, Elenitsas R, Buchanan MA, Leahy DS, Watanabe R, Kirsch IR, Kim EJ, Clark RA.
Rook AH, et al. Among authors: watanabe r.
Blood. 2015 Sep 17;126(12):1452-61. doi: 10.1182/blood-2015-02-630335. Epub 2015 Jul 30.
Blood. 2015.
PMID: 26228486
Free PMC article.
Clinical Trial.